血管内腹主动脉修补术后总死亡率的预测因素 - 一项单中心研究。

IF 0.9 4区 医学 Q4 PERIPHERAL VASCULAR DISEASE
Vascular Pub Date : 2025-08-01 Epub Date: 2024-06-13 DOI:10.1177/17085381241262350
Mária Rašiová, Martin Koščo, Veronika Pavlíková, Marek Hudák, Matej Moščovič, Ladislav Kočan
{"title":"血管内腹主动脉修补术后总死亡率的预测因素 - 一项单中心研究。","authors":"Mária Rašiová, Martin Koščo, Veronika Pavlíková, Marek Hudák, Matej Moščovič, Ladislav Kočan","doi":"10.1177/17085381241262350","DOIUrl":null,"url":null,"abstract":"<p><p>ObjectivesA current and ongoing challenge is to reduce patient mortality after endovascular abdominal aortic repair (EVAR). This study aimed to assess the predictors of all-cause mortality after EVAR.MethodsData regarding the demographic characteristics, comorbidities, laboratory values, selected anatomical factors, post-EVAR treatment, surveillance and complications of patients who underwent elective EVAR for non-ruptured abdominal aortic aneurysm (AAA) between January 2010 and January 2021 were evaluated. Mortality was assessed until 10 October 2023. Multivariate analyses were performed after adjusting for age, hypertension, diabetes mellitus, dyslipidaemia, sex, smoking, number of lumbar arteries, patency of inferior mesenteric artery (IMA), IMA diameter and reinterventions.ResultsThis study included 196 patients (183 men and 13 women) with a mean age of 72.4 ± 7.67 years. The overall mortality rate during a mean follow-up period of 5.75 ± 3.1 years was 50.0% (<i>N</i> = 98). The 2-, 5- and 10-year mortality rates were 9.7%, 32.0% and 66.6%, respectively. The mortality rates decreased by 59% in patients with reinterventions (hazard ratio [HR]: 0.41; 95% confidence interval [CI]: 0.23-0.73; <i>p</i> = .002) and by 59% in patients treated with angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) (HR: 0.41; 95% CI: 0.26-0.66; <i>p</i> < .001). Chronic anticoagulation was associated with 2.09-fold higher mortality (HR: 2.09; 95% CI: 1.19-3.67; <i>p</i> = .010), and coronary artery disease (CAD) was associated with 1.74-fold higher mortality (HR: 1.74; 95% CI: 1.09-2.78; <i>p</i> = .021). Pre-EVAR AAA diameter and 1-year post-EVAR sac diameter were positively associated with mortality (HR: 1.05; 95% CI: 1.03-1.08; <i>p</i> < .001, and HR: 1.05; 95% CI: 1.03-1.07; <i>p</i> < .001, respectively), that is, an increase of pre-EVAR and/or 1-year post-EVAR AAA diameter by 1 mm was associated with a 5% higher risk of all-cause mortality.ConclusionsReinterventions and treatment with ACE inhibitors or ARBs may be associated with decreased post-EVAR mortality. A greater pre-EVAR, a post-EVAR AAA diameter, CAD and chronic anticoagulation were associated with higher all-cause mortality post-EVAR.</p>","PeriodicalId":23549,"journal":{"name":"Vascular","volume":" ","pages":"746-755"},"PeriodicalIF":0.9000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Predictors of overall mortality after endovascular abdominal aortic repair - A single centre study.\",\"authors\":\"Mária Rašiová, Martin Koščo, Veronika Pavlíková, Marek Hudák, Matej Moščovič, Ladislav Kočan\",\"doi\":\"10.1177/17085381241262350\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>ObjectivesA current and ongoing challenge is to reduce patient mortality after endovascular abdominal aortic repair (EVAR). This study aimed to assess the predictors of all-cause mortality after EVAR.MethodsData regarding the demographic characteristics, comorbidities, laboratory values, selected anatomical factors, post-EVAR treatment, surveillance and complications of patients who underwent elective EVAR for non-ruptured abdominal aortic aneurysm (AAA) between January 2010 and January 2021 were evaluated. Mortality was assessed until 10 October 2023. Multivariate analyses were performed after adjusting for age, hypertension, diabetes mellitus, dyslipidaemia, sex, smoking, number of lumbar arteries, patency of inferior mesenteric artery (IMA), IMA diameter and reinterventions.ResultsThis study included 196 patients (183 men and 13 women) with a mean age of 72.4 ± 7.67 years. The overall mortality rate during a mean follow-up period of 5.75 ± 3.1 years was 50.0% (<i>N</i> = 98). The 2-, 5- and 10-year mortality rates were 9.7%, 32.0% and 66.6%, respectively. The mortality rates decreased by 59% in patients with reinterventions (hazard ratio [HR]: 0.41; 95% confidence interval [CI]: 0.23-0.73; <i>p</i> = .002) and by 59% in patients treated with angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) (HR: 0.41; 95% CI: 0.26-0.66; <i>p</i> < .001). Chronic anticoagulation was associated with 2.09-fold higher mortality (HR: 2.09; 95% CI: 1.19-3.67; <i>p</i> = .010), and coronary artery disease (CAD) was associated with 1.74-fold higher mortality (HR: 1.74; 95% CI: 1.09-2.78; <i>p</i> = .021). Pre-EVAR AAA diameter and 1-year post-EVAR sac diameter were positively associated with mortality (HR: 1.05; 95% CI: 1.03-1.08; <i>p</i> < .001, and HR: 1.05; 95% CI: 1.03-1.07; <i>p</i> < .001, respectively), that is, an increase of pre-EVAR and/or 1-year post-EVAR AAA diameter by 1 mm was associated with a 5% higher risk of all-cause mortality.ConclusionsReinterventions and treatment with ACE inhibitors or ARBs may be associated with decreased post-EVAR mortality. A greater pre-EVAR, a post-EVAR AAA diameter, CAD and chronic anticoagulation were associated with higher all-cause mortality post-EVAR.</p>\",\"PeriodicalId\":23549,\"journal\":{\"name\":\"Vascular\",\"volume\":\" \",\"pages\":\"746-755\"},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Vascular\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/17085381241262350\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/6/13 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"PERIPHERAL VASCULAR DISEASE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vascular","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17085381241262350","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/13 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0

摘要

目标:降低血管内腹主动脉修补术(EVAR)后患者死亡率是当前和持续面临的挑战。本研究旨在评估 EVAR 术后全因死亡率的预测因素:方法:评估了2010年1月至2021年1月期间因非破裂性腹主动脉瘤(AAA)而接受择期EVAR手术的患者的人口统计学特征、合并症、实验室值、选定的解剖因素、EVAR术后治疗、监测和并发症等方面的数据。死亡率评估截至 2023 年 10 月 10 日。在调整了年龄、高血压、糖尿病、血脂异常、性别、吸烟、腰动脉数量、肠系膜下动脉(IMA)通畅度、IMA直径和再干预等因素后,进行了多变量分析:该研究包括 196 名患者(183 名男性和 13 名女性),平均年龄为 72.4 ± 7.67 岁。在平均 5.75 ± 3.1 年的随访期内,总死亡率为 50.0%(N = 98)。2年、5年和10年的死亡率分别为9.7%、32.0%和66.6%。接受再干预治疗的患者死亡率降低了 59%(危险比 [HR]:0.41;95% 置信区间 [CI]:0.23-0.73;P = .002),接受血管紧张素转换酶 (ACE) 抑制剂或血管紧张素 II 受体阻滞剂 (ARB) 治疗的患者死亡率降低了 59%(HR:0.41;95% 置信区间 [CI]:0.26-0.66;P < .001)。慢性抗凝与死亡率增加 2.09 倍相关(HR:2.09;95% CI:1.19-3.67;p = .010),冠状动脉疾病(CAD)与死亡率增加 1.74 倍相关(HR:1.74;95% CI:1.09-2.78;p = .021)。EVAR前的AAA直径和EVAR后1年的囊直径与死亡率呈正相关(HR:1.05;95% CI:1.03-1.08;p < .001,HR:1.05;95% CI:1.03-1.07;p < .001),即EVAR前和/或EVAR后1年的AAA直径每增加1毫米,全因死亡风险就增加5%:结论:再次干预和使用 ACE 抑制剂或 ARBs 治疗可能与 EVAR 术后死亡率的降低有关。EVAR前AAA直径增大、EVAR后AAA直径增大、CAD和长期抗凝与EVAR后全因死亡率升高有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Predictors of overall mortality after endovascular abdominal aortic repair - A single centre study.

ObjectivesA current and ongoing challenge is to reduce patient mortality after endovascular abdominal aortic repair (EVAR). This study aimed to assess the predictors of all-cause mortality after EVAR.MethodsData regarding the demographic characteristics, comorbidities, laboratory values, selected anatomical factors, post-EVAR treatment, surveillance and complications of patients who underwent elective EVAR for non-ruptured abdominal aortic aneurysm (AAA) between January 2010 and January 2021 were evaluated. Mortality was assessed until 10 October 2023. Multivariate analyses were performed after adjusting for age, hypertension, diabetes mellitus, dyslipidaemia, sex, smoking, number of lumbar arteries, patency of inferior mesenteric artery (IMA), IMA diameter and reinterventions.ResultsThis study included 196 patients (183 men and 13 women) with a mean age of 72.4 ± 7.67 years. The overall mortality rate during a mean follow-up period of 5.75 ± 3.1 years was 50.0% (N = 98). The 2-, 5- and 10-year mortality rates were 9.7%, 32.0% and 66.6%, respectively. The mortality rates decreased by 59% in patients with reinterventions (hazard ratio [HR]: 0.41; 95% confidence interval [CI]: 0.23-0.73; p = .002) and by 59% in patients treated with angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) (HR: 0.41; 95% CI: 0.26-0.66; p < .001). Chronic anticoagulation was associated with 2.09-fold higher mortality (HR: 2.09; 95% CI: 1.19-3.67; p = .010), and coronary artery disease (CAD) was associated with 1.74-fold higher mortality (HR: 1.74; 95% CI: 1.09-2.78; p = .021). Pre-EVAR AAA diameter and 1-year post-EVAR sac diameter were positively associated with mortality (HR: 1.05; 95% CI: 1.03-1.08; p < .001, and HR: 1.05; 95% CI: 1.03-1.07; p < .001, respectively), that is, an increase of pre-EVAR and/or 1-year post-EVAR AAA diameter by 1 mm was associated with a 5% higher risk of all-cause mortality.ConclusionsReinterventions and treatment with ACE inhibitors or ARBs may be associated with decreased post-EVAR mortality. A greater pre-EVAR, a post-EVAR AAA diameter, CAD and chronic anticoagulation were associated with higher all-cause mortality post-EVAR.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Vascular
Vascular 医学-外周血管病
CiteScore
2.30
自引率
9.10%
发文量
196
审稿时长
6-12 weeks
期刊介绍: Vascular provides readers with new and unusual up-to-date articles and case reports focusing on vascular and endovascular topics. It is a highly international forum for the discussion and debate of all aspects of this distinct surgical specialty. It also features opinion pieces, literature reviews and controversial issues presented from various points of view.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信